Fresenius Medical Care AG & Co. KGaA’s Outperform Rating Reaffirmed at BNP Paribas (FME)

Fresenius Medical Care AG & Co. KGaA (ETR: FME)‘s stock had its “outperform” rating reaffirmed by research analysts at BNP Paribas in a report released on Thursday, AnalystRatings.Net reports. They currently have a €62.00 ($80.52) target price on the stock.

A number of other analysts have also recently weighed in on FME. Analysts at Jefferies Group reiterated a “hold” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note to investors on Wednesday, May 29th. Separately, analysts at Sanford C. Bernstein reiterated an “outperform” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note to investors on Tuesday, May 28th. They now have a €61.50 ($79.87) price target on the stock. Finally, analysts at M.M. Warburg Investment Research reiterated a “buy” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note to investors on Friday, May 24th. They now have a €61.00 ($79.22) price target on the stock.

Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and nine have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of €55.70 ($72.34).

Shares of Fresenius Medical Care AG & Co. KGaA (ETR: FME) opened at 52.474 on Thursday. Fresenius Medical Care AG & Co. KGaA has a one year low of €47.982 and a one year high of €60.24. The stock’s 50-day moving average is currently €56.72.

Fresenius Medical Care AG & Co KGaA is a Germany-based holding and kidney dialysis company, operating in the fields of dialysis products and dialysis services.